Article

Update on Kaposi’s sarcoma: A gammaherpesvirus-induced malignancy

Current Infectious Disease Reports 04/2012; 5(1):85-92. DOI:10.1007/s11908-003-0069-8 pp.85-92

ABSTRACT Since the beginning of the AIDS epidemic, Kaposi’s sarcoma (KS) has been one of the most visible manifestations of this disease
and one of the most distressing for affected patients. The discovery in 1994 of a new gammaherpesvirus, called Kaposi’s sarcoma-associated
herpesvirus, has led to increased understanding of the pathogenesis of this disease and the potential for new specific therapy.
In addition, the development of highly active antiretroviral therapy has had a substantial impact on the incidence of KS in
countries where it is available and on the course of established disease. Finally, recent advances in our understanding of
angiogenesis have the potential of leading to new KS therapies. In this article we review some of the recent advances in the
epidemiology and pathogenesis of KS, review the current treatment of this disease, and discuss several therapeutic approaches
that are now under development.

0 0
 · 
0 Bookmarks
 · 
36 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

active antiretroviral therapy
 
AIDS epidemic
 
current treatment
 
epidemiology
 
Kaposi’s sarcoma
 
new gammaherpesvirus
 
new KS therapies
 
new specific therapy
 
patients
 
recent advances
 
substantial impact